|
Market Closed -
Nasdaq Stockholm
17:00:00 21/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 19.84 SEK | +2.69% |
|
-0.50% | -12.21% |
| 08-20 | SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-20 | Synact Pharma reports narrower operating loss | FW |
Company Valuation: SynAct Pharma AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,703 | 2,416 | 314.1 | 416.8 | 1,205 | 1,111 | - | - |
| Change | - | -34.75% | -87% | 32.69% | 189.2% | -7.82% | - | - |
| Enterprise Value (EV) 1 | 3,703 | 2,416 | 314.1 | 370 | 1,152 | 1,094 | 1,136 | 1,111 |
| Change | - | -34.75% | -87% | 17.8% | 211.31% | -5.06% | 3.87% | -2.19% |
| P/E | -53.1x | -22.6x | -1.33x | -4.31x | -10.4x | -13.3x | -26.1x | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.7x | -0x | 0.1x | -2.4x | 0.4x | 0.5x | - |
| Capitalization / Revenue | - | - | - | - | - | 25.1x | 51.4x | 14.3x |
| EV / Revenue | - | - | - | - | - | 24.7x | 52.6x | 14.3x |
| EV / EBITDA | - | - | -1.4x | -4.11x | -9.88x | -23.7x | -38.7x | 39x |
| EV / EBIT | - | - | -1.4x | -4.11x | -9.88x | -23.5x | -38.5x | 39x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.68 | -3.6 | -6.64 | -2.08 | -2.17 | -1.49 | -0.76 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 44.25 | 21.6 | 77.9 |
| EBITDA 1 | - | - | -224.5 | -89.98 | -116.5 | -46.22 | -29.38 | 28.5 |
| EBIT 1 | - | - | -224.5 | -89.98 | -116.5 | -46.48 | -29.5 | 28.5 |
| Net income 1 | -69.3 | -99.2 | -215.8 | -82.4 | -110.8 | -42.32 | -25.64 | 28.5 |
| Net Debt 1 | - | - | - | -46.75 | -53.41 | -17.48 | 24.86 | - |
| Reference price 2 | 142.40 | 81.50 | 8.83 | 8.96 | 22.60 | 19.84 | 19.84 | 19.84 |
| Nbr of stocks (in thousands) | 26,006 | 29,648 | 35,571 | 46,487 | 53,330 | 55,998 | - | - |
| Announcement Date | 11/02/22 | 17/02/23 | 23/02/24 | 18/02/25 | 18/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.32x | 24.71x | -23.66x | - | 117M | |
| 35.74x | 12.95x | 26.26x | 0.55% | 1,119B | |
| 30.06x | - | - | 1.99% | 651B | |
| 33.82x | 7.82x | 16.26x | 2.59% | 468B | |
| 20.93x | 4.96x | 12.28x | 2.66% | 374B | |
| 22.59x | 5.81x | 14.4x | 2.75% | 302B | |
| 21.37x | 4.4x | 12.49x | 1.99% | 259B | |
| 27.79x | 7.17x | 12.73x | 2.3% | 238B | |
| 13.71x | 4.87x | 10.23x | 3.75% | 208B | |
| -44.65x | 6.45x | 25.18x | 2.26% | 181B | |
| Average | 14.80x | 8.79x | 11.80x | 2.31% | 380B | |
| Weighted average by Cap. | 25.51x | 8.51x | 18.70x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SYNACT Stock
- Valuation SynAct Pharma AB
Select your edition
All financial news and data tailored to specific country editions
